Navigation Links
IDRI and Zydus sign agreement for development of IDRI's vaccine candidate for visceral leishmaniasis
Date:7/25/2013

Seattle, WA, and Ahmedabad, India, July 25, 2013: In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease.

Known as Kala-Azar in India, VL is transmitted by the bite of an infected sand fly. There are over 500,000 new VL cases and 50,000 associated deaths each year. VL is the most severe form of leishmaniasis, affecting vital organs and, if left untreated, the disease can be fatal. A vaccine is considered essential to control and eliminate the disease. Currently, leishmaniasis occurs in four continents and is considered to be endemic in 88 countries; 72 of those are developing countries, with the disease being most common in India, Nepal, Bangladesh, Sudan and Brazil. While there are drugs to treat the disease, they are expensive and often toxic. To date, a safe and efficacious vaccine to prevent this disease does not exist.

Zydus and IDRI will collaborate to conduct clinical activities in India with the goal of developing, registering and marketing this vaccine candidate for the prevention of VL, while achieving the objective of global access that is, ensuring the vaccine is affordable to and accessible by all people in need. Conducting trials in India, where there are real-life situations of disease exposure, is critical to determining the effectiveness of the IDRI's VL vaccine candidate and ensuring it is approved and available within endemic countries.

IDRI's VL vaccine candidate, LEISH-F3+GLA-SE, is the product of more than 20 years of research and development supported by the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. The defined, purified, recombinant vaccine is comprised of two fused Leishmania parasite proteins and an adjuvant to stimulate a protective immune response against the parasite. After completion of a Phase 1 clinical trial of 36 U.S. adult volunteers to test safety and immunogenicity, the vaccine was shown to be safe and to induce potent immune responses in healthy volunteers.

Speaking of the partnership, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group, said, "Zydus has always been committed to working with partners and collaborating to bridge unmet healthcare needs. By partnering with IDRI on this very important mission, we will be taking an all important step to eradicate visceral leishmaniasis, which is a huge healthcare burden."

Dr. Steven G. Reed, IDRI Founder and President added, "Zydus' expertise and breadth of development and commercialization experience will be instrumental in getting IDRI's VL vaccine to the people who need it most. We are appreciative of Zydus' commitment to this program. This is an excellent example of cooperating to help combat a devastating disease without consideration for a profit motive. IDRI could not ask for a better partner in this endeavor."


'/>"/>

Contact: Lee Schoentrup
lee.schoentrup@idri.org
206-858-6064
Infectious Disease Research Institute
Source:Eurekalert

Related biology news :

1. Eurofins MWG Operon and Floragenex close co-marketing agreement for RAD discovery and RAD genotyping
2. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
3. Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
4. Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies Rapid Optical Alcohol Detection & Biometric Test
5. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
6. University of Colorado and Orphan Technologies sign agreement
7. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
8. Ukraine, EU Advance on Visa Facilitation Agreement
9. CHOP and BGI strengthen partnership with agreement on pediatric brain tumor collaboration
10. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
11. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
Breaking Biology News(10 mins):
(Date:1/13/2017)... Kalamazoo, Michigan (PRWEB) , ... January 13, 2017 ... ... manufacture and market products containing an organic compound called fulvic acid that farms, ... , Hydroponics operations that grow cannabis are among the fastest growing segments of ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful ... laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered ...
(Date:1/12/2017)... ... January 12, 2017 , ... Huffman Engineering, Inc. , ... who will work in the company’s Lincoln office as a chemical engineer. In ... control systems for customers in the life science manufacturing and water/wastewater industries. , Prior ...
(Date:1/12/2017)... Jan. 12, 2017   Protein Sciences Corporation ... of Flublok Influenza Vaccine ®, announced today ... had good safety results and induced strong neutralizing ... The product is expected to advance into human ... addition, the Institute of Technology in Immunobiologicals of ...
Breaking Biology Technology: